BridgeBio Pharma Inc to Host Achondroplasia Investor Webinar Transcript
Thank you for standing by. At this time, I would like to welcome everyone to the BridgeBio Pharma achondroplasia investor webinar. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. (Operator Instructions)
I would now like to turn the call over to Justin To. You may begin.
Good morning, and welcome to the BridgeBio webcast for the infigratinib program for achondroplasia. Before we begin today, I'd like to remind our audience that we will be making forward-looking statements today. For a discussion of these risks, please see BridgeBio's most recent financial statement. This is an exciting time for our program as we have recently achieved last participant last visit of PROPEL 3, our Phase 3 clinical trial in achondroplasia, and we expect to announce top-line results by the end of the first quarter.
Today, we are excited to be joined by Dr. Janet Legare, Professor and Genetics
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
